August 2025
1. VAN AMELSFOORT RM, Gonzalez P, Simoes R, Jansen EPM, et al
   A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.
   Eur J Cancer. 2025;228:115672.
   

   >> Share

   
   July 2025
2. GANAME S, Walter T, Durand A, Lievre A, et al
   Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.
   Eur J Cancer. 2025;225:115450.
   

   >> Share

   
   May 2025
3. ROSANU NM, Gervaso L, Cella CA, Fazio N, et al
   Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.
   Eur J Cancer. 2025;224:115521.
   

   >> Share

   
   March 2025
4. KAMP D, May AM, Adenis A, Capela A, et al
   Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.
   Eur J Cancer. 2025;218:115278.
   

   >> Share

   
   
5. SATOH T, Barthelemy P, Nogova L, Honda K, et al
   Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
   Eur J Cancer. 2025;218:115262.
   

   >> Share

   
   February 2025
6. ISHIDA H, Sunakawa Y, Kodera Y, Yoshida K, et al
   Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.
   Eur J Cancer. 2025;219:115322.
   

   >> Share

   
   November 2024
7. GEERTS JFM, Pape M, Vissers PAJ, Verhoeven RHA, et al
   Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands.
   Eur J Cancer. 2024;214:115137.
   

   >> Share

   
   October 2024
8. FUJITANI K, Kurokawa Y, Wada R, Takeno A, et al
   Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival.
   Eur J Cancer. 2024;213:115080.
   

   >> Share

   
   
9. SCHIRIZZI A, Donghia R, De Nunzio V, Renna N, et al
   High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma.
   Eur J Cancer. 2024;213:115066.
   

   >> Share

   
   June 2024
10. KROESE TE, Bronzwaer S, van Rossum PSN, Schoppman SF, et al
    European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
    Eur J Cancer. 2024;204:114062.
    

    >> Share

    
    May 2024
11. RAIMONDI A, Kim YW, Kang WK, Langley RE, et al
    Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Eur J Cancer. 2024;203:114043.
    

    >> Share

    
    April 2024
12. DIERKS S, Buchholz SM, Konig A, Liersch T, et al
    Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
    Eur J Cancer. 2024;204:114076.
    

    >> Share

    
    January 2024
13. ZHAO P, Li S, Du X
    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go.
    Eur J Cancer. 2024;199:113554.
    

    >> Share

    
    
14. VAN DER SLUIS K, Taylor SN, Kodach LL, van Dieren JM, et al
    Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.
    Eur J Cancer. 2024;199:113541.
    

    >> Share

    
    December 2023
15. TAIEB J, Bennouna J, Penault-Llorca F, Basile D, et al
    Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
    Eur J Cancer. 2023;195:113370.
    

    >> Share

    
    September 2023
16. AIX PONCE S, Cousin S, Dubos P, Belcaid L, et al
    Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2023;193:113309.
    

    >> Share

    
    
17. MUTI HS, Rocken C, Behrens HM, Loffler CML, et al
    Deep learning trained on lymph node status predicts outcome from gastric cancer histopathology: a retrospective multicentric study.
    Eur J Cancer. 2023;194:113335.
    

    >> Share

    
    July 2023
18. KALFF MC, Dijksterhuis WPM, Wagner AD, Oertelt-Prigione S, et al
    Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
    Eur J Cancer. 2023;187:114-123.
    

    >> Share

    
    June 2023
19. ASPLUND JPU, Mackenzie HA, Markar SR, Lagergren JHF, et al
    Surgeon proficiency gain and survival after gastrectomy for gastric adenocarcinoma: A population-based cohort study.
    Eur J Cancer. 2023;186:91-97.
    

    >> Share

    
    
20. JIA K, Chen Y, Xie Y, Chong X, et al
    Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
    Eur J Cancer. 2023;189:112931.
    

    >> Share

    
    April 2023
21. PORTH I, Hirsch D, Ceribas Y, Weidner P, et al
    Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Eur J Cancer. 2023;183:119-130.
    

    >> Share

    
    February 2023
22. KAWAKAMI H, Sunakawa Y, Inoue E, Matoba R, et al
    Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
    Eur J Cancer. 2023;184:10-20.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share